07:59 AM EDT, 07/28/2025 (MT Newswires) -- Quanterix ( QTRX ) said Monday it has commercially launched two new phospho-tau assays, growing its blood-based biomarker portfolio for Alzheimer's disease and neurodegeneration.

The new p-Tau 205 and p-Tau 212 assays enable precise detection of tau phosphorylation sites, biomarkers increasingly related to early and progressive stages of Alzheimer's disease, the company said.

Quanterix ( QTRX ) shares were up 6.2% in recent premarket activity.